GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...

GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.

China-based MindRank’s oral glucagon-like peptide-1 receptor agonist (GLP-1RA) has achieved up to 10.5% weight loss in a ...

Novo Nordisk has ended a partnership with telehealth company Him & Hers, after launching the collaboration less than two ...

Innovent Biologics Inc. announced June 27 that it gained National Medical Products Administration’s (NMPA) approval of mazdutide as a new weight loss therapy for obese or overweight patients in China.

Price differences are especially pertinent with these weight loss drugs, which are officially called glucagon-like peptide-1 receptor agonists (GLP-1RA), due to the emergence of compounded ...

Multimodal AOMs were associated with the highest preoperative weight loss among patients with high BMI undergoing bariatric surgery.

Compounded vs non-compounded GLP-1 RA drug products are associated with an increased risk for adverse events such as nausea and diarrhea.

Israel: A new study published in JAMA Network Open highlights a key safety insight for patients with type 2 diabetes taking ...